Stock Scorecard
Stock Summary for Fulgent Genetics Inc (FLGT) - $23.27 as of 2/20/2026 1:15:00 PM EST
Total Score
13 out of 30
Safety Score
31 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for FLGT
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for FLGT
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for FLGT
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for FLGT
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for FLGT (31 out of 100)
| Stock Price Rating (Max of 10) | 7 |
| Historical Stock Price Rating (Max of 10) | 7 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 8 |
| Book Value to Price (Max of 10) | 8 |
| Analyst Buy Ratings (Max of 5) | 2 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for FLGT
Financial Details for FLGT
Company Overview |
|
|---|---|
| Ticker | FLGT |
| Company Name | Fulgent Genetics Inc |
| Country | N/A |
| Description | Fulgent Genetics, Inc. (FLGT), headquartered in Temple City, California, is a leading provider of innovative genetic testing and diagnostic solutions with a focus on precision medicine. The company offers a comprehensive range of genomic analyses and COVID-19 diagnostics, showcasing its commitment to enhancing patient care and addressing urgent public health challenges. Fulgent's continual investment in technological advancements and its strategic adaptability within a rapidly evolving healthcare landscape position it for sustained growth. With a robust foundation in genetic testing, Fulgent is well-equipped to capitalize on emerging opportunities, solidifying its leadership in the industry. |
| Sector Name | HEALTHCARE |
| Industry Name | DIAGNOSTICS & RESEARCH |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 2/27/2026 |
Stock Price History |
|
| Last Day Price | 23.27 |
| Price 4 Years Ago | 29.78 |
| Last Day Price Updated | 2/20/2026 1:15:00 PM EST |
| Last Day Volume | 227,642 |
| Average Daily Volume | 202,459 |
| 52-Week High | 31.04 |
| 52-Week Low | 14.57 |
| Last Price to 52 Week Low | 59.71% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 37.00 |
| Sector PE | 148.47 |
| 5-Year Average PE | -16.23 |
| Free Cash Flow Ratio | 6.11 |
| Industry Free Cash Flow Ratio | 81.06 |
| Sector Free Cash Flow Ratio | 31.12 |
| Current Ratio Most Recent Quarter | 7.01 |
| Total Cash Per Share | 3.81 |
| Book Value Per Share Most Recent Quarter | 36.49 |
| Price to Book Ratio | 0.70 |
| Industry Price to Book Ratio | 572.58 |
| Sector Price to Book Ratio | 33.63 |
| Price to Sales Ratio Twelve Trailing Months | 2.32 |
| Industry Price to Sales Ratio Twelve Trailing Months | 4.45 |
| Sector Price to Sales Ratio Twelve Trailing Months | 23.44 |
| Analyst Buy Ratings | 1 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 30,912,400 |
| Market Capitalization | 719,331,548 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | -98.60% |
| Annual Earnings Growth | 74.55% |
| Reported EPS 12 Trailing Months | -1.40 |
| Reported EPS Past Year | -0.44 |
| Reported EPS Prior Year | 0.49 |
| Net Income Twelve Trailing Months | -42,983,000 |
| Net Income Past Year | -42,708,000 |
| Net Income Prior Year | -167,825,000 |
| Quarterly Revenue Growth YOY | 17.20% |
| 5-Year Revenue Growth | 54.19% |
| Operating Margin Twelve Trailing Months | -18.30% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 117,641,000 |
| Total Cash Past Year | 55,144,000 |
| Total Cash Prior Year | 97,473,000 |
| Net Cash Position Most Recent Quarter | 115,683,000 |
| Net Cash Position Past Year | 52,651,000 |
| Long Term Debt Past Year | 2,493,000 |
| Long Term Debt Prior Year | 2,964,000 |
| Total Debt Most Recent Quarter | 1,958,000 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 1,133,228,000 |
| Total Stockholder Equity Prior Year | 1,136,101,000 |
| Total Stockholder Equity Most Recent Quarter | 1,125,888,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -19,849,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.64 |
| Free Cash Flow Past Year | -19,255,000 |
| Free Cash Flow Prior Year | 4,796,000 |
Options |
|
| Put/Call Ratio | 2.36 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -1.10 |
| MACD Signal | -0.94 |
| 20-Day Bollinger Lower Band | 21.19 |
| 20-Day Bollinger Middle Band | 26.07 |
| 20-Day Bollinger Upper Band | 30.94 |
| Beta | 0.87 |
| RSI | 30.12 |
| 50-Day SMA | 22.27 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 2/20/2026 10:52:21 PM EST |